Jeste Dilip V, Depp Colin A, Palmer Barton W
Department of Psychiatry, University of California, San Diego, USA.
Schizophr Bull. 2006 Jan;32(1):121-8. doi: 10.1093/schbul/sbj001. Epub 2005 Sep 28.
The capacity of individuals with schizophrenia to make decisions related to research participation or clinical treatment has received increasing empirical attention. A number of studies have compared patients with schizophrenia to nonpsychiatric comparison subjects (NPCs) on structured measures of decision-making capacity. In this review, we evaluated the magnitude of the difference between schizophrenia and NPC groups reported across these studies, as well as the influence of sample characteristics on observed effect sizes. We also computed the effect sizes of group differences in psychopathology and cognitive deficits. Twelve studies met the search criteria; a majority of them reported data using the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) or for Treatment (MacCAT-T). The mean effect size (evaluated in terms of Cohen's d) for group differences on the Understanding subscale of the MacCAT instruments was 0.88 (SD = 0.40); it was twice as high among inpatient samples as among outpatients. Similar differences were observed in terms of Appreciation and Reasoning subscales, but the effect sizes for Expression of Choice were small (mean d = 0.29, SD = 0.24). Notably, these observed effect sizes were generally smaller than those for differences between schizophrenia and NPC groups in psychopathology (mean d = 2.06, SD = 1.03) and cognition (mean d = 1.01, SD = 0.61). The published studies demonstrate a substantial heterogeneity in decision-making capacity among people with schizophrenia, as well as among NPCs, suggesting that the presence of schizophrenia does not necessarily mean the patient has impairment in capacity.
精神分裂症患者做出与研究参与或临床治疗相关决策的能力越来越受到实证关注。一些研究在结构化决策能力测量方面,将精神分裂症患者与非精神科对照受试者(NPC)进行了比较。在本综述中,我们评估了这些研究报告的精神分裂症组与NPC组之间差异的大小,以及样本特征对观察到的效应量的影响。我们还计算了精神病理学和认知缺陷方面组间差异的效应量。十二项研究符合检索标准;其中大多数使用麦克阿瑟临床研究能力评估工具(MacCAT-CR)或治疗能力评估工具(MacCAT-T)报告数据。MacCAT工具理解分量表上组间差异的平均效应量(以科恩d值评估)为0.88(标准差 = 0.40);住院样本中的效应量是门诊样本中的两倍。在欣赏和推理分量表方面也观察到类似差异,但选择表达分量表的效应量较小(平均d = 0.29,标准差 = 0.24)。值得注意的是,这些观察到的效应量通常小于精神分裂症组与NPC组在精神病理学(平均d = 2.06,标准差 = 1.03)和认知(平均d = 1.01,标准差 = 0.61)方面的差异。已发表的研究表明,精神分裂症患者以及NPC在决策能力方面存在很大异质性,这表明患有精神分裂症不一定意味着患者存在能力受损。